PLA-PEG Nanoparticles Improve the Anti-Inflammatory Effect of Rosiglitazone on Macrophages by Enhancing Drug Uptake Compared to Free Rosiglitazone
Source abstract
Abstract
Among cardiovascular diseases, atherosclerosis remains the first cause of death in the United States of America and Europe, as it leads to myocardial infarction or stroke. The high prevalence of heart diseases is due to the difficulty in diagnosing atherosclerosis, since it can develop for decades before symptoms occur, and to the complexity of the treatment since targets are also important components of the host defenses. The antidiabetics thiazolidinediones, among which is rosiglitazone (RSG), have demonstrated anti-atherosclerotic effect in animal models, and are therefore promising candidates for the improvement of atherosclerosis management. Nevertheless, their administration is hindered by the insurgence of severe side effects. To overcome this limitation, rosiglitazone has been encapsulated into polymeric nanoparticles, which permit efficient delivery to its nuclear target, and selective delivery to the site of action, allowing the reduction of unwanted effects. In the present work, we describe nanoparticle formulation using polylactic acid (PLA) coupled to polyethylene glycol (PEG), their characterization, and their behavior on RAW264.7 macrophages, an important target in atherosclerosis treatment. RSG nanocarriers showed no toxicity on cells at all concentrations tested, an anti-inflammatory effect in a dose-dependent manner, up to 5 times more efficient than the free molecule, and an increased RSG uptake which is consistent with the effect shown. These biodegradable nanoparticles represent a valid tool to be further investigated for the treatment of atherosclerosis.
Source: crossref · Quality: baseline
Research context
OpenAlex topics: Peroxisome Proliferator-Activated Receptors · NF-κB Signaling Pathways · Peptidase Inhibition and Analysis
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
Institut Galien Paris-Sud, CNRS, Univ. Paris-Sud, Université Paris-Saclay, 92296 Châtenay-Malabry, France
Funding
Agence Nationale de la Recherche
References (31)
Show source-provided references
1. The vulnerable atherosclerotic plaque: In vivo identification and potential therapeutic avenues10.1136/heartjnl-2014-307099 ↗
2. From vulnerable plaque to vulnerable patient—Part iii: Executive summary of the screening for heart attack prevention and education (shape) task force report10.1016/j.amjcard.2006.03.002 ↗
3. Macrophages in the pathogenesis of atherosclerosis10.1016/j.cell.2011.04.005 ↗
4. Surface coating mediates the toxicity of polymeric nanoparticles towards human-like macrophages10.1016/j.ijpharm.2014.11.042 ↗
5. Surface-modified biodegradable nanoparticles’ impact on cytotoxicity and inflammation response on a co-culture of lung epithelial cells and human-like macrophages10.1166/jbn.2016.2126 ↗
6. Endocytosis and exocytosis of nanoparticles in mammalian cells
7. A new concept for macromolecular therapeutics in cancer-chemotherapy—Mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs
8. Cancer-related inflammation10.1038/nature07205 ↗
9. Development of a nanoprecipitation method intended for the entrapment of hydrophilic drugs into nanoparticles10.1016/j.ejps.2004.09.011 ↗
10. Degradable controlled-release polymers and polymeric nanoparticles: Mechanisms of controlling drug release10.1021/acs.chemrev.5b00346 ↗
11. Expression of the peroxisome proliferator-activated receptor γ (pparγ) in human atherosclerosis and regulation in macrophages by colony stimulating factors and oxidized low density lipoprotein10.1073/pnas.95.13.7614 ↗
12. Ppar-γ agonists inhibit production of monocyte inflammatory cytokines10.1038/34184 ↗
13. The many faces of pparγ10.1016/j.cell.2005.11.026 ↗
14. Peroxisome proliferator-activated receptor gamma ligands inhibit development of atherosclerosis in ldl receptor-deficient mice10.1172/JCI10370 ↗
15. A retrospective evaluation of congestive heart failure and myocardial ischemia events in 14,237 patients with type 2 diabetes mellitus enrolled in 42 short-term, double-blind, randomized clinical studies with rosiglitazone10.1002/pds.1615 ↗
16. Perspectives and opportunities for nanomedicine in the management of atherosclerosis10.1038/nrd3578 ↗
17. Nanomedicine-based strategies for treatment of atherosclerosis10.1016/j.molmed.2013.12.001 ↗
18. Rosiglitazone-loaded nanospheres for modulating macrophage-specific inflammation in obesity10.1016/j.jconrel.2013.06.012 ↗
19. Preventing diet-induced obesity in mice by adipose tissue transformation and angiogenesis using targeted nanoparticles10.1073/pnas.1603840113 ↗
20. Nanomedicines of hedgehog inhibitor and ppar-gamma agonist for treating liver fibrosis10.1007/s11095-013-1239-5 ↗
21. Formulation parameters influencing the physicochemical characteristics of rosiglitazone-loaded cationic lipid emulsion10.1007/s12272-012-0711-9 ↗
22. Multimodal theranostic nanoformulations permit magnetic resonance bioimaging of antiretroviral drug particle tissue-cell biodistribution10.7150/thno.22764 ↗
23. Design and development of amphotericin b bearing polycaprolactone microparticles for macrophage targeting10.1166/jbn.2011.1196 ↗
24. Biodegradation and biocompatibility of pla and plga microspheres10.1016/S0169-409X(97)00048-3 ↗
25. Stealth properties to improve therapeutic efficacy of drug nanocarriers10.1155/2013/374252 ↗
26. Disposition and ultimate fate of a pla-peg sustained release polymer after intra-articular injection10.1016/j.joca.2016.01.958 ↗
27. Rapid colorimetric assay for cellular growth and survival—Application to proliferation and cyto-toxicity assays10.1016/0022-1759(83)90303-4 ↗
28. Recent trends in preparation of poly(lactide-co-glycolide) nanoparticles by mixing polymeric organic solution with antisolvent10.1155/2015/794601 ↗
29. (1996). Handbook of organic solvent properties. Handbook of Organic Solvent Properties, Butterworth-Heinemann.
30. Formulation of functionalized plga–peg nanoparticles for in vivo targeted drug delivery10.1016/j.biomaterials.2006.09.047 ↗
31. Drug release kinetics and transport mechanisms of non-degradable and degradable polymeric delivery systems10.1517/17425241003602259 ↗